Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Blood ; 121(10): 1850-7, 2013 Mar 07.
Article in English | MEDLINE | ID: mdl-23303820

ABSTRACT

Scott syndrome, a bleeding disorder caused by defective phospholipid scrambling, has been associated with mutations in the TMEM16F gene. The role of TMEM16F in apoptosis- or agonist-induced phosphatidylserine (PS) exposure was studied in platelets from a Scott syndrome patient and control subjects. Whereas stimulation of control platelets with the BH3-mimetic ABT737 resulted in 2 distinct fractions with moderate and high PS exposure, the high PS-exposing fraction was markedly delayed in Scott platelets. High, but not moderate, PS exposure in platelets was suppressed by chelation of intracellular Ca(2+), whereas caspase inhibition completely abolished ABT737-induced PS exposure in both Scott and control platelets. On the other hand, high PS exposure induced by the Ca(2+)-mobilizing agonists convulxin/thrombin fully relied on mitochondrial depolarization and was virtually absent in Scott platelets. Finally, PS exposure induced by collagen/thrombin was partly affected in Scott platelets, and the residual PS positive fraction was insensitive to inhibition of caspases or mitochondrial depolarization. In conclusion, TMEM16F is not required for, but enhances, caspase-dependent PS exposure; convulxin-/thrombin-induced PS exposure is entirely dependent on TMEM16F, whereas collagen/thrombin-induced PS exposure results from 2 distinct pathways, one of which involves mitochondrial depolarization and is mediated by TMEM16F.


Subject(s)
Apoptosis , Blood Coagulation Disorders/pathology , Blood Platelets/pathology , Calcium/metabolism , Phosphatidylserines/metabolism , Phospholipid Transfer Proteins/metabolism , Platelet Activation , Anoctamins , Blood Coagulation Disorders/metabolism , Blood Platelets/metabolism , Case-Control Studies , Caspases/metabolism , Crotalid Venoms/pharmacology , Cyclophilins/metabolism , Flow Cytometry , Hemostatics/pharmacology , Humans , Lectins, C-Type , Mitochondria/drug effects , Mitochondria/metabolism , Thrombin/pharmacology
2.
Eur J Pharmacol ; 693(1-3): 1-6, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-22959357

ABSTRACT

Ribavirin in combination with interferon-α is the standard treatment for chronic hepatitis C, but often induces severe anemia forcing discontinuation of the therapy. Whereas suppression of bone marrow by interferon may impact on the production of erythrocytes, it has been suggested that accumulation of ribavirin in erythrocytes induces alterations causing an early removal of these cells by the mononuclear phagocytic system. Externalization of phosphatidylserine, which is exclusively present in the cytoplasmic leaflet of the plasma membrane, is a recognition signal for phagocytosis in particular of apoptotic cells. Here, we demonstrate that surface exposure of phosphatidylserine upon prolonged treatment of erythrocytes with ribavirin results mainly from inactivation of the aminophospholipid translocase, an ATP-dependent lipid pump, which specifically transports phosphatidylserine from the outer to the inner leaflet of the plasma membrane. Inactivation is due to severe ATP depletion, although competitive inhibition by ribavirin or its phosphorylated derivatives cannot be excluded. Phospholipid scramblase, responsible for collapse of lipid asymmetry, appears to be of minor importance as erythrocytes of patients with the Scott syndrome, lacking Ca(2+)-induced lipid scrambling, are equally sensitive to ribavirin treatment. Neither the antioxidant N-acetylcysteine nor the pan-caspase inhibitor Q-VD-OPH did affect ribavirin-induced phosphatidylserine exposure, suggesting that oxidative stress or apoptotic-related mechanisms are not involved in this process. In conclusion, we propose that spontaneous loss of lipid asymmetry, not corrected by aminophospholipid translocase activity, is the mechanism for ribavirin-induced phosphatidylserine exposure that may contribute to ribavirin-induced anemia.


Subject(s)
Antiviral Agents/pharmacology , Erythrocytes/drug effects , Ionomycin/pharmacology , Phosphatidylserines/metabolism , Phospholipid Transfer Proteins/antagonists & inhibitors , Ribavirin/pharmacology , Adenosine Triphosphate/metabolism , Cells, Cultured , Erythrocytes/metabolism , Hemolysis/drug effects , Humans , Phospholipid Transfer Proteins/metabolism
3.
Mol Membr Biol ; 20(1): 83-91, 2003.
Article in English | MEDLINE | ID: mdl-12745928

ABSTRACT

Membrane-perturbing agents that cause transformation of biconcave erythrocytes into echinocytes or stomatocytes were used to investigate the influence of erythrocyte shape on the rate of Ca(2+)-induced scrambling of phospholipids. Erythrocytes were treated with a variety of lipid-soluble compounds to induce these shape changes, followed by incubation with calcium and ionomycin to activate lipid scramblase. Prothrombinase activity of the cells was used to monitor the rate of surface exposure of phosphatidylserine, which is taken as a measure of scramblase activity. Echinocytes show an enhanced rate of scrambling, whereas stomatocytes show a reduced rate, relative to normocytes. This phenomenon appears to correlate with enhanced and diminished micro-exovesicle shedding from echinocytes and stomatocytes, respectively. It is concluded that the rate of calcium-induced phosphatidylserine exposure (rate of lipid scrambling) in erythrocytes depends for a considerable part on the cells' ability to form microvesicles.


Subject(s)
4-Chloro-7-nitrobenzofurazan/analogs & derivatives , Calcium/metabolism , Erythrocytes/cytology , Erythrocytes/metabolism , Phosphatidylserines/metabolism , Phospholipid Transfer Proteins , 4-Chloro-7-nitrobenzofurazan/pharmacology , Calcium/pharmacology , Carrier Proteins/drug effects , Carrier Proteins/metabolism , Cell Size/drug effects , Cells, Cultured , Chlorpromazine/pharmacology , Detergents/pharmacology , Dibucaine/pharmacology , Erythrocytes/drug effects , Humans , Ionophores/pharmacology , Lidocaine/pharmacology , Membrane Proteins/drug effects , Membrane Proteins/metabolism , Phosphatidylcholines/pharmacology , Secretory Vesicles/metabolism , Thromboplastin/drug effects , Thromboplastin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...